The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.
Clinical Trials
Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma
HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit profile compared with best alternative care (BAC), according to a study published online April 7 in the Annals of Surgical Oncology.
ctDNA After Surgery Identified Patients at High Risk for Early Recurrence in Stage III Melanoma Trial
Measurements of circulating tumor DNA (ctDNA) before adjuvant targeted therapy and during follow-up identified patients with stage III melanoma at high risk for early disease recurrence, according to results of an analysis of patients from the COMBI-AD trial published recently in The Lancet Oncology.
First Patient Receives KSQ-004EX for Advanced Cancer
A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.